Announcement • Jun 03
Regener8 Resources NL (ASX:R8R) acquired Orichalcum d.o.o. for AUD 0.96 million. Regener8 Resources NL (ASX:R8R) entered into a binding agreement to acquire Srebrenica North Project in Bosnia and Herzegovina for AUD 0.96 million on March 3, 2026. A cash consideration of AUD 0.08 million will be paid by Regener8 Resources NL. The consideration consists of 8 million common equity of Regener8 Resources NL to be issued for assets of Srebrenica North Project in Bosnia and Herzegovina. As part of consideration, AUD 0.08 million is paid towards assets of Srebrenica North Project in Bosnia and Herzegovina.
The transaction is subject to approval of offer by acquirer shareholders and consummation of due diligence investigation.
As of May 6, 2026, Regener8 Resources NL is pleased to advise that, at the Company’s Extraordinary General Meeting (EGM) held earlier today, shareholders voted in favor of the resolution to approve the acquisition of 100% of the issued capital of Orichalcum d.o.o. As of May 13, 2026, Completion of the acquisition, which will see Regener8 acquire 100% of the issued capital of Orichalcum d.o.o., is expected in the coming week following standard regulatory and administrative steps, including the formal transfer of company shares.
Regener8 Resources NL (ASX:R8R) completed the acquisition of Srebrenica North Project in Bosnia and Herzegovina on June 01, 2026. New Risk • May 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 50% per year over the past 5 years. Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Revenue is less than US$1m (AU$23k revenue, or US$17k). Market cap is less than US$10m (AU$8.60m market cap, or US$6.23m). Board Change • Apr 15
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Director Petar Tomasevic was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 
